CONNECTA Therapeutics S.L. is a biotechnology company that develops new treatments for CNS unmet medical needs.
The company is initially focus on the clinical development of a new “first-in-class” molecule for the treatment of fragile X syndrome (FXS). FXS is the most common cause of hereditary intellectual disability and there are no therapeutic interventions currently available.
The molecule was discovered after evaluating more than 30 molecular and cellular targets. The molecule has been proven, in in vitro tests and in vivo in animal models, to be an excellent neuroplasticity modulator with a great extension profile for other neurodevelopmental disorders (Rett syndrome, Down syndrome and autism spectrum disorders, among others).
Company Details
- Employees
- 8
- Founded
- 2019
- Address
- Barcelona, Barcelona 08028, Es
- Phone
- +34 649 82 40 40
- in****@****ics.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- connectatherapeutics.com
- Keywords
- neuroplasticity and neurology.
- HQ
- Barcelona, Barcelona
Connecta Therapeutics Questions
Connecta Therapeutics's helpline number is +34 649 82 40 40
Connecta Therapeutics's website is connectatherapeutics.com
Connecta Therapeutics's LinkedIn profile is https://es.linkedin.com/company/connecta-therapeutics
Connecta Therapeutics has
8 employees.
View email and phone details for 8
employees at Connecta Therapeutics.
Connecta Therapeutics's industry is
Biotechnology Research
Connecta Therapeutics's top competitors are
Ipronics,
Esencia Foods,
Moa Foodtech,
Premium Fertility,
Accure Therapeutics,
Kintsugi Therapeutics,
Gate2brain,
Splicebio,
Ona Therapeutics,
Inbrain Neuroelectronics.
Connecta Therapeutics's support email address is info@connectatherapeutics.com
Connecta Therapeutics's categories are Biotechnology Research
Connecta Therapeutics's founding year is 2019
